Lowering Biologic Drug Costs Through Regulatory Reform

The Problem of High Drug Costs

• 💡 Millions of Americans struggle to afford essential medicines, leading to rationing prescriptions and skipping doses.
• 📈 Biologic drugs, made from living cells, account for over half of all drug spending despite being only 5% of prescriptions, with some costing up to half a million dollars annually.
• ⚠️ The traditional system for generics broke down for biologics due to pharmaceutical industry lobbying that rigged rules and created "fake distinctions" to block cheaper alternatives.

Regulatory Barriers and Market Failure

• 🚫 Outdated FDA approval processes and regulatory barriers have protected monopolies, stifled competition, and slowed the entry of lower-cost biosimilars.
• 💰 It can cost hundreds of millions of dollars and years of red tape to bring just one biosimilar to American patients, lagging far behind Europe.
• 💸 High biologic costs are ultimately paid by the everyday American worker through health insurance deductions and employer contributions.

Trump Administration's Reform Actions

• ✅ The FDA is issuing new draft guidance to streamline biosimilar approval, reducing the need for large, expensive human trials by relying on advanced testing.
• ✂️ Unnecessary red tape is being cut by consolidating outdated guidance into one rulebook, aiming to halve the time to market (from 5-8 years to 2.5-5 years) and save companies $100 million in development costs.
• 🔄 Reforms will promote interchangeability, allowing pharmacists to substitute biosimilars for brand-name biologics, similar to traditional generics.

Expected Impact and Future Goals

• 💲 Biosimilars have already saved Americans over $56 billion since 2015, costing 50% less than brand-name counterparts and driving down brand prices by 25%.
• 🎯 The goal is to foster more intense competition in the market, as prices significantly drop only when two or three biosimilars are available.
• 🗣️ Key asks include patients pushing for biosimilars, insurance plans designing for accessibility, and governors leveraging Medicaid savings.